Histone deacetylase inhibitors (HDACIs) are promising anticancer agents and their use in combination with conventional anticancer drugs is currently under investigation. We previously reported cell line-specific upregulation of ABCG2, a multidrug resistance transporter shown to control oral bioavailability and CNS penetration, by the HDACI romidepsin, although the precise mechanism in a particular cell line remains to be determined. The aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor that can be activated by numerous environmental contaminants and has been shown to be a client protein of Heat shock protein 90 (Hsp90). A xenobiotic response element (XRE) was defined in the ABCG2 promoter and was shown to mediate AhR signaling. Activated AhR was found to be associated with the ABCG2 promoter only in cell line models that respond to romidepsin with ABCG2 upregulation. Our data suggest that romidepsin acetylated Hsp70 and inhibited the chaperone function of Hsp90, thereby allowing the dissociation of AhR from Hsp90. The dissociation of AhR from Hsp90 may be a prerequisite for the differential upregulation of ABCG2 by romidepsin. Increasing our understanding of the mechanism(s) governing differential upregulation of ABCG2 in response to romidepsin could provide an insight into strategies needed to tackle resistance to HDACIs in cancer therapeutics.
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Introduction
ABCG2 is a ubiquitous ATP-binding cassette (ABC) multidrug resistance transporter that plays a significant role in normal tissue protection, stem cell maintenance and clinical pharmacology (1) . Its overexpression confers resistance in cancer cell lines to a variety of cancer chemotherapeutic agents such as mitoxantrone, topotecan, and methotrexate (2-7). However, little is known about the mechanisms underlying its regulation.
Histone deacetylase inhibitors (HDACI) such as romidepsin (also known as FK228 or depsipeptide) and vorinostat (suberoylanilide hydroxamic acid or SAHA) were found to be potent anticancer agents, capable of inducing cell cycle arrest and apoptosis in cancer cells (8) .
A number of HDACIs are currently in clinical trials as both monotherapy and in combination therapy because these compounds have been shown to potentiate the cytotoxic effects of other anticancer drugs in experimental models. We and others have demonstrated that multidrug resistance transporters (including ABCG2 and MDR-1) can be upregulated upon treatment with various HDACIs (9-13), potentially hindering drug response in combination therapy. Therefore, a better understanding about the mechanism for activation of these transporters upon HDACI treatment could help develop strategies for the prevention of drug resistance.
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that belongs to the basic helix-loop-helix/Per-ARNT-Sim (bHLH-PAS) family (14) . It regulates the transcription of genes encoding xenobiotic metabolizing enzymes and also mediates the toxic effects caused by environmental carcinogens such as dioxins and polycyclic aromatic hydrocarbons. In the unliganded state, the AhR is associated with two molecules of the chaperone Hsp90, an immunophilin-like protein XAP2, and the Hsp90-interacting acidic protein Luciferase reporter assays. A series of human ABCG2 promoter constructs with progressive deletions at the 5'-end has been previously described (30) . Two new reporter constructs were prepared with the putative XRE sequences deleted from the full length ABCG2 promoter ( Figure 2 ; Δ-60/-52 and Δ-198/-189). The ABCG2 promoter/firefly luciferase fusion genes (200 ng DNA) were transfected in S1 cells using Fugene 6 (Roche, Indianapolis, IN). The pGL3-Basic (promoterless) plasmid, encoding firefly luciferase (Promega, Madison, WI), was 8 lysed in buffer containing 0.2 M Tris pH 7.4, 1% Triton X-100, 0.02% β-mercaptoethanol, and complete mini EDTA-free protease inhibitor cocktail tablets (Roche), followed by sonication for homogenization. Whole cell lysates prepared were separated by SDS-PAGE and subjected to immunoblot analysis with the respective antibodies for AhRR (ab85666, Abcam, Cambridge, MA) and GAPDH (American Research Products, Belmont, MA). The antigen-antibody complex was analyzed with an Odyssey (Li-Cor, Licolin, NE) infrared imaging system after incubation with a 1:10,000 dilution of goat anti-mouse (IRDye800CW) or anti-rabbit (IRDye680) secondary antibody (Li-Cor).
Co-immunoprecipitation.
For coimmunoprecipitation experiments, cells were lysed in IP buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% Triton X-100, and protease inhibitor cocktail tablets), homogenized by sonication, and centrifuged at 13,000 rpm for 2 minutes at 4 Taq DNA polymerase (Bioline) was used to amplify 1 μL of either the immunoprecipitated DNA using the specific antibody, the immunoprecipitate using a normal IgG control antibody, or a 1:10 dilution of input chromatin. Preliminary experiments were carried out to determine optimal PCR conditions so that the yield of PCR products was dependent on the amount of input DNA (data not shown). The conditions for the PCR reactions were as follows: immunoprecipitated DNA versus input DNA (total chromatin). Only 10% of the total input was used in the PCR reactions and they were run as the 'input' lanes in gel electrophoresis.
Percentage enrichment was calculated accordingly. ChIP assays were repeated thrice using different chromatin preparations.
Flow cytometry. ABCG2-mediated efflux activity in romidepsin-pretreated cells was determined by flow cytometric assays as described previously (31) . Cells after a 24-h treatment of romidepsin (10 ng/mL) or vorinostat (5 μM) were incubated in 1 μM pheophorbide A (PhA) with or without 10 μM ABCG2-specific inhibitor fumitremorgin C (FTC) in complete medium Samples were analyzed on a LSRFortessa Cell Analyzer (BD Biosciences, San Jose, CA).
PhA fluorescence was detected with a 488-nm argon laser and a 670-nm bandpass filter. At least 10,000 events were collected for all flow cytometry studies. with the induction of permissive histone modification marks at the ABCG2 promoter in these cells (12) . In our continued effort aiming at understanding the regulation of ABCG2, we pursued an earlier report suggesting that ABCG2 could be regulated by AhR agonists (32). Our result demonstrated that ABCG2 can be upregulated by B(a)P (an AhR agonist; 24 h) in several cell lines including S1, SW620 and MCF-7 cells (Figure 1 ). This upregulation can be reversed in AhR-silenced cells ( Table 2 ). Of note, the cell lines were chosen to cover a range of basal ABCG2 expression levels ( Figure 2 ). While ABCG2 levels in S1 and SW620 were marginally detectable, MCF-7 and SF295 express much higher basal levels of ABCG2. As controls for comparison, the upregulation of MDR1 and p21, two genes commonly found to be elevated by HDACIs, was not affected by AhR knockdown (Figure 1 Figure 1 ) in all cell lines tested. Moreover, both MDR1 and p21 levels were not changed by B(a)P, suggesting that the AhR-related ABCG2 upregulation observed is specific. It is also interesting to note that a typical AhR-responsive gene, CYP1A1, was not affected by romidepsin treatment in all cell lines tested ( Figure 1 ).
Results

Induction
An XRE cis-element is required for the activation of ABCG2 promoter activity by B(a)P.
Since AhR was potentially involved in romidepsin-mediated upregulation of ABCG2 in S1 cells and -31/+ 396). Using the PROMO virtual library for the identification of putative transcription factor binding sites, two putative XRE elements were predicted on the ABCG2 proximal promoter ("-60 to -52" and "-198 to -189") based on the TRANSFAC database (36) . B(a)Pmediated upregulation of ABCG2 promoter activity could be abolished in the -198/-189 deleted reporter construct (Figure 3 ), suggesting that this XRE region is important for ABCG2 regulation.
Moreover, activation of the ABCG2 promoter activity was also abolished in AhR-silenced cells (Supplementary Figure 2) . The reporter assay was also repeated in S1 cells treated with romidepsin (data not shown). As we have previously noted, romidepsin aberrantly increases the luciferase activity of the Renilla vector (12) . Therefore, the specific effect of romidepsin on the XRE could not be confirmed by this assay. It is known that Hsp90 chaperone activity is regulated by reversible acetylation and is controlled by the deacetylase HDAC6 (39) . As a class I HDAC inhibitor, romidepsin has been reported to have only a weak effect on HDAC 6 (27,28) but it has been shown to disrupt the chaperone function of Hsp90 and induce apoptosis in human non-small-cell lung cancer cells (23). Hsp70 is an important co-chaperone protein with Hsp90. It was reported that one of the class I HDACs is the deacetylase of Hsp70 and that romidepsin treatment can increase acetylation of Hsp70 (40) . Of note, Hsp70 is required for the assembly of Hsp90-client protein complexes (41) . More recently, it has been reported that romidepsin may disrupt the chaperone function of Hsp90 indirectly through acetylation of Hsp70 (42) . Therefore, immunoprecipitation experiments were also performed to assess the effect of romidepsin and vorinostat on acetylation of Hsp90/Hsp70 and the association between Hsp90 and AhR.
Romidepsin increases the association of AhR with XRE at the
As expected for the pan-HDAC inhibitor, vorinostat induced hyperacetylation of both Hsp90 and Hsp70 in S1 cells ( Figure 6A ). On the other hand, romidepsin cannot inhibit 
HDAC6 and therefore it did not cause Hsp90 hyperacetylation but instead only Hsp70 hyperacetylation in S1 cells ( Figure 6A) . Consistent with the effect of Hsp90/Hsp70 hyperacetylation on Hsp90 chaperone function and agreeing with the result in Figure 5A , romidepsin or vorinostat treatment (4 h) was found to deplete the binding of AhR to Hsp90 in S1 cells ( Figure 6B ). Interestingly, no Hsp70 and Hsp90 acetylation was observed in the nonresponsive SW620 cells after exposing to romidepsin or vorinostat ( Figure 6A ), which is believed to account for the unchanged association between AhR and Hsp90 ( Figure 6B) . As a control, B(a)P treatment was able to dissociate AhR from Hsp90 in both S1 and SW620 cells 
Romidepsin increased ABCG2 efflux activity only in the responsive S1 cells. Consistent with the PCR analysis ( Figure 1 and Table 2 ), increased PhA efflux (as measured by ΔMFI) was also noted in romidepsin or vorinostat-treated S1 cells (Figure 8 ). On the other hand, PhA efflux remained unchanged or was slightly decreased in SW620 and SF295 cells, respectively, upon romidepsin or vorinostat treatment (Figure 8 ).
Discussion
This study extends our earlier report about the modulation of the ABCG2 gene by HDACIs. We found that romidepsin increased ABCG2 expression in selected cancer cell lines and this modulation was accompanied by histone modifications such as an increase in histone acetylation at the ABCG2 promoter (12) . Unlike MDR1, the induction of ABCG2 following romidepsin exposure was found to be cell line specific (12) . While differential display (44) Hsp90 is an important molecular chaperone playing a critical role in maintaining the stability and function of its client proteins (17, 18) , and Hsp90 acetylation has been shown to impair the chaperone function of Hsp90 (23) and target the client proteins for degradation (48, 49) . Hsp70 is an important co-chaperone protein of Hsp90 and is required for the assembly of Hsp90-client protein complexes (41) . It has been reported that romidepsin may disrupt the chaperone function of Hsp90 indirectly through acetylation of Hsp70 (42) . Since the chaperone function of Hsp90 also determines AhR protein stability, AhR protein expression was also assessed. Concurrent with release of AhR and translocation to the nucleus, AhR degradation also occurs following B(a)P exposure (50) . We observed this phenomenon following B(a)P exposure in both S1 and SW620 cells. Similarly, our data showed that AhR degrades substantially after 16 h exposure to romidepsin in S1 cells ( Figure 5A , "-MG132" panel, Input).
In contrast, the Hsp90 chaperone was found to protect AhR from degradation in the romidepsin non-responsive SW620 cells ( Figure 5A The negative feedback mechanism involving the AhR repressor (AhRR) was also examined to determine its role in the lack of ABCG2 upregulation in the non-responsive cell lines. To this end, the constitutive expression of AhRR was not altered by romidepsin treatment ( Figure 7A ). In the romidepsin non-responsive SW620 cell line, no AhRR binding to the ABCG2 promoter can be detected ( Figure 7B ). Therefore, AhRR is not likely to participate in the cell line-specific regulation of ABCG2 by romidepsin treatment.
The biological/functional consequence of the cell line-specific upregulation of ABCG2 was also investigated. Consistent with the ABCG2 mRNA analysis, an increase in ABCG2-mediated efflux was observed in romidepsin-or vorinostat-treated S1 cells (Figure 8 ). It is noteworthy that ABCG2 protein expression or FTC-inhibitable efflux was not observed in S1 cells under basal condition. Given that ABCG2 upregulation may lead to treatment failure when HDACI (romidepsin) is used in combination with other chemotherapeutic agents, strategies could be designed to modulate the AhR pathway therapeutically for the circumvention of drug resistance. Moreover, since constitutive overexpression of AhR is commonly observed in several cancer types including lung and esophageal cancers (56,57), the involvement of this AhRmediated upregulation of ABCG2 in the acquired multidrug resistance and poor prognosis of these cancers may deserve investigation.
Taken together, the AhR signaling pathway was demonstrated to be involved in the cell line-specific upregulation of ABCG2 by romidepsin treatment. A working model is illustrated in Figure 9 . The AhR-Hsp90 interaction appears to represent a novel pathway for regulating ABCG2 expression in cancer cells. Whether other therapeutic genes will be similarly regulated is a subject for further study. experiments is presented. The reporter assay was also repeated in S1 cells treated with romidepsin (data not shown). As we have previously noted, romidepsin aberrantly increases the luciferase activity of the Renilla vector (12) . Therefore, the specific effect of romidepsin on the XRE could not be confirmed by this assay. 
